Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Deep Learning for Flap Perfusion Detection (DL-FPA)

23. september 2026 oppdatert av: Jing Xu

Application of a Deep Learning-Based Model for Detecting Flap Perfusion Abnormalities After First-Stage Auricular Reconstruction in Congenital Microtia Patients

The aim of this study is to develop a convolutional neural network-based image recognition model to identify flap perfusion abnormalities after first-stage auricular reconstruction in patients with congenital microtia. In addition, the study seeks to evaluate the real-world performance of this model when applied to clinical flap monitoring.

The main questions addressed are:

  • Can an artificial intelligence (AI) image recognition model accurately detect flap perfusion abnormalities from photographs of the reconstructed ear?
  • Compared with conventional clinical monitoring, does AI-based image recognition alter the incidence of flap-related complications?
  • How accurate is AI-based detection of flap abnormalities, and how satisfied are patients and healthcare providers with this monitoring approach?

The study is divided into two phases.

  • In phase I, investigators will collect postoperative photographs of reconstructed ears and relevant clinical data from patients with congenital microtia undergoing first-stage auricular reconstruction. Images will be annotated based on the clinical judgement of experienced healthcare professionals, and these data will be used to train a convolutional neural network image recognition model. The model's ability to identify flap perfusion abnormalities will then be assessed through internal validation.
  • In phase II, the clinical performance of traditional monitoring methods will be compared with AI-based image recognition monitoring.

Patients admitted between July 2027 and December 2027 who meet the inclusion criteria will receive conventional clinical flap monitoring and routine follow-up and will comprise the control group.

Patients admitted between January 2028 and June 2028 who meet the inclusion criteria will receive flap monitoring using the convolutional neural network-based image recognition module in addition to standard clinical management and follow-up and will comprise the study group.

Investigators will compare postoperative complication rates, the accuracy of detecting flap perfusion abnormalities, and satisfaction among patients and healthcare providers between the two groups.

Participants will:

  • Undergo flap monitoring after first-stage auricular reconstruction according to the clinical follow-up schedule;
  • Provide, or cooperate in the acquisition of, reconstructed ear photographs and relevant clinical data as required by the study;
  • Receive routine follow-up and health education;
  • In the study group, undergo flap monitoring assisted by the image recognition module in addition to conventional monitoring.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

232

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Shanghai, Kina, 201112
        • EYE & ENT Hospital, Fudan University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 40 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 6-40 years;
  • Typical microtia morphology consistent with the diagnostic criteria in Chinese Plastic Surgery;
  • Patients after first-stage total auricular reconstruction who have not yet undergone second-stage surgery;
  • The participant or family member is able to use a smartphone.

Exclusion Criteria:

  • Abnormal coagulation or other relevant laboratory findings;
  • Absence of normal fascial coverage on the affected ear, or presence of eczema, infection, or other local abnormalities on the affected side;
  • Severe cognitive impairment or psychiatric disorders;
  • Significant dysfunction of major organs;
  • The patient or family member does not consent to participation in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Control group

Patients with congenital microtia will undergo first-stage auricular reconstruction with standard flap assessment and routine follow-up, without AI-based remote flap image monitoring.

Eksperimentell: Intervention group

Participants will undergo first-stage auricular reconstruction and receive AI-assisted remote flap monitoring postoperatively, with scheduled image acquisition and flap assessment conducted according to the study protocol.

In addition to routine outpatient follow-up, an AI image recognition-based remote intelligent monitoring system led by specialist nurses will be implemented. After discharge, patients will receive daily prompts to upload photographs of the reconstructed ear. The AI system will analyse images in real time: if classified as normal, it will provide standard care recommendations; if classified as abnormal, it will automatically alert the clinical team. Specialist nurses will manually review abnormal images and, as appropriate, request repeat imaging, intensify home care and increase monitoring frequency, or report to the supervising physician and instruct the patient to return to the hospital for further management.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Complication rate
Tidsramme: Assessed 3 months postoperatively

Complications will be identified and recorded based on outpatient review notes and follow-up records. The complication rate will be calculated as:

Complication rate = (number of patients with complications after first-stage auricular reconstruction / total number of patients) × 100%.

The following common postoperative complications after first-stage auricular reconstruction will be included: hematoma requiring re-hemostasis, infection, flap necrosis, cartilage exposure, and deformation of the auricular framework.

Assessed 3 months postoperatively

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient satisfaction
Tidsramme: Assessed 3 months postoperatively

Patient satisfaction will be assessed using a self-designed satisfaction questionnaire comprising 15 items divided into five domains: consultation process and environment (3 items), quality of medical and nursing services (3 items), attitude of medical and nursing staff (3 items), health education (3 items), and use of the case management platform (3 items). Each item will be rated on a 3-point Likert scale from "dissatisfied" to "satisfied," scored 1-3, yielding a total score range of 15-45. The satisfaction score will be calculated as the sum of all item scores, with higher scores indicating greater patient satisfaction.

Assessed 3 months postoperatively
System complication detection rate
Tidsramme: Assessed at 3 months postoperatively

The system complication detection rate will be calculated as:

System complication detection rate = (number of cases classified as abnormal by the system and clinically confirmed to have auricular reconstruction complications / total number of cases classified as abnormal by the system) × 100%.

Assessed at 3 months postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

22. september 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

23. september 2026

Først innsendt som oppfylte QC-kriteriene

23. september 2026

Først lagt ut (Faktiske)

29. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared with external researchers due to patient privacy protection and institutional data policy. Aggregated study results will be reported in publications.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere